Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

NCT06163404 · View on ClinicalTrials.gov ↗

Study Summary

Pilot study of bioabsorbable implant and delivery device for correction of septal deviation.

Interventions

  • DEVICE Implantation of Spirair Nasal Device using the Spirair delivery system.

Study Locations (8)

Louisiana

  • Sinus and Nasal Specialists of LA — Baton Rouge
  • Tandem Clinical Research — Marrero

Alabama

  • Alabama Nasal and Sinus Center — Birmingham

California

  • Breathe Clear Institute — Torrance

Kentucky

  • Kentuckiana Ear, Nose & Throat — Louisville

New York

  • Albany ENT & Allergy Services, PC — Albany

Pennsylvania

  • Specialty Physicians — Bethlehem

Washington

  • Ear Nose Throat & Allergy Associates — Puyallup

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2023-11-01
Est. Completion 2027-05
Phase NA

Sponsor

Spirair

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06163404

The ClinicalTrials.gov registry entry for NCT06163404 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spirair, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Nasal Airway Obstruction appearing as the primary indexed condition, and to 1 intervention — of which Implantation of Spirair Nasal Device using the Spirair delivery system. is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06163404 reports 8 study locations spanning 7 distinct geographic areas — top geographies include Louisiana, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06163404 about?

NCT06163404 is a clinical study titled "Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant". Pilot study of bioabsorbable implant and delivery device for correction of septal deviation.

What is the current status of trial NCT06163404?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 102 participants. The study started on 2023-11-01. Estimated completion is 2027-05.

What conditions does trial NCT06163404 study?

This clinical trial studies the following conditions: Nasal Airway Obstruction, Nasal Septal Deviation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06163404?

The interventions under investigation include: Implantation of Spirair Nasal Device using the Spirair delivery system. (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06163404?

This trial is sponsored by Spirair, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06163404 being conducted?

This trial has 8 study locations across Alabama, California, Kentucky, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial